Recent Publications – Food Allergy Oral Immunotherapy

In: | on December 29, 2022 | by | 0 Comments

Below is a collection of scientific papers sharing recent clinical progress made in the field of food allergen oral immunotherapy. If you wish to learn more about whether oral immunotherapy could be an option for your child, please reach out to us at [email protected] or read more about our program at oralimmunotherapy.ca

  1. OBH J, Beyer K, Abbas A, Fernandez-Rivas M, Turner PJ, Blumchen K, et al. Efficacy and Safety of Oral Immunotherapy With AR101 in European Children With a Peanut Allergy (ARTEMIS): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial. Lancet Child Adolesc Health (2020) 4(10):728–39. doi: 10.1016/S2352-4642(20)30234-0
    PubMed Abstract | CrossRef Full Text | Google Scholar
  2. Rodriguez Del Rio P, Escudero C, Sanchez-Garcia S, Ibanez MD, Vickery BP. Evaluating Primary End Points in Peanut Immunotherapy Clinical Trials. J Allergy Clin Immunol (2019) 143(2):494–506. doi: 10.1016/j.jaci.2018.09.035
    PubMed Abstract | CrossRef Full Text | Google Scholar
  3. Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, et al. Oral Immunotherapy for Peanut Allergy (PACE): A Systematic Review and Meta-Analysis of Efficacy and Safety. Lancet (2019) 393(10187):2222–32. doi: 10.1016/S0140-6736(19)30420-9
    PubMed Abstract | CrossRef Full Text | Google Scholar
  4. Investigators PGoC, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med (2018) 379(21):1991–2001. doi: 10.1056/NEJMoa1812856
    PubMed Abstract | CrossRef Full Text | Google Scholar
  5. Blumchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G, et al. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children With Peanut Allergy. J Allergy Clin Immunol Pract (2019) 7(2):479–91 e10. doi: 10.1016/j.jaip.2018.10.048
    PubMed Abstract | CrossRef Full Text | Google Scholar
  6. Wood RA. Food Allergen Immunotherapy: Current Status and Prospects for the Future. J Allergy Clin Immunol (2016) 137(4):973–82. doi: 10.1016/j.jaci.2016.01.001
    PubMed Abstract | CrossRef Full Text | Google Scholar
  7. Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral Immunotherapy for Treatment of Egg Allergy in Children. N Engl J Med (2012) 367(3):233–43. doi: 10.1056/NEJMoa1200435
    PubMed Abstract | CrossRef Full Text | Google Scholar
  8. Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA, et al. Long-Term Treatment With Egg Oral Immunotherapy Enhances Sustained Unresponsiveness That Persists After Cessation of Therapy. J Allergy Clin Immunol (2016) 137(4):1117–27.e10. doi: 10.1016/j.jaci.2015.12.1316
    PubMed Abstract | CrossRef Full Text | Google Scholar
  9. Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early Oral Immunotherapy in Peanut-Allergic Preschool Children is Safe and Highly Effective. J Allergy Clin Immunol (2017) 139(1):173–81.e8. doi: 10.1016/j.jaci.2016.05.027
    PubMed Abstract | CrossRef Full Text | Google Scholar
  10. Anagnostou K. Food Immunotherapy for Children With Food Allergies: State of the Art and Science. Curr Opin Pediatr (2018) 30(6):798–805. doi: 10.1097/MOP.0000000000000684
    PubMed Abstract | CrossRef Full Text | Google Scholar
  11. Kulis MD, Patil SU, Wambre E, Vickery BP. Immune Mechanisms of Oral Immunotherapy. J Allergy Clin Immunol (2018) 141(2):491–8. doi: 10.1016/j.jaci.2017.12.979
    PubMed Abstract | CrossRef Full Text | Google Scholar
  12. Begin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, et al. Phase 1 Results of Safety and Tolerability in a Rush Oral Immunotherapy Protocol to Multiple Foods Using Omalizumab. Allergy Asthma Clin Immunol (2014) 10(1):7. doi: 10.1186/1710-1492-10-7
    PubMed Abstract | CrossRef Full Text | Google Scholar
  13. Tang ML, Martino DJ. Oral Immunotherapy and Tolerance Induction in Childhood. Pediatr Allergy Immunol (2013) 24(6):512–20. doi: 10.1111/pai.12100
    PubMed Abstract | CrossRef Full Text | Google Scholar
  14. Gernez Y, Nowak-Wegrzyn A. Immunotherapy for Food Allergy: Are We There Yet? J Allergy Clin Immunol Pract (2017) 5(2):250–72. doi: 10.1016/j.jaip.2016.12.004
    PubMed Abstract | CrossRef Full Text | Google Scholar
  15. Calvani M, Bianchi A, Imondi C, Romeo E. Oral Desensitization in IgE-Mediated Food Allergy: Effectiveness and Safety. Pediatr Allergy Immunol (2020) 31 Suppl 24:49–50. doi: 10.1111/pai.13171
    PubMed Abstract | CrossRef Full Text | Google Scholar
  16. Gruzelle V, Juchet A, Martin-Blondel A, Michelet M, Chabbert-Broue A, Didier A. Benefits of Baked Milk Oral Immunotherapy in French Children With Cow’s Milk Allergy. Pediatr Allergy Immunol (2020) 31(4):364–70. doi: 10.1111/pai.13216
    PubMed Abstract | CrossRef Full Text | Google Scholar
  17. Nagakura KI, Sato S, Yanagida N, Nishino M, Asaumi T, Ogura K, et al. Oral Immunotherapy in Japanese Children With Anaphylactic Peanut Allergy. Int Arch Allergy Immunol (2018) 175(3):181–8. doi: 10.1159/000486310
    PubMed Abstract | CrossRef Full Text | Google Scholar
  18. Takaoka Y, Maeta A, Takahashi K, MI Y, Takahashi S, Muroya T, et al. Effectiveness and Safety of Double-Blind, Placebo-Controlled, Low-Dose Oral Immunotherapy With Low Allergen Egg-Containing Cookies for Severe Hen’s Egg Allergy: A Single-Center Analysis. Int Arch Allergy Immunol (2019) 180(4):244–9. doi: 10.1159/000502956
    PubMed Abstract | CrossRef Full Text | Google Scholar
  19. Kauppila TK, Paassilta M, Kukkonen AK, Kuitunen M, Pelkonen AS, Makela MJ. Outcome of Oral Immunotherapy for Persistent Cow’s Milk Allergy From 11 Years of Experience in Finland. Pediatr Allergy Immunol (2019) 30(3):356–62. doi: 10.1111/pai.13025
    PubMed Abstract | CrossRef Full Text | Google Scholar
  20. Vazquez-Cortes S, Jaqueti P, Arasi S, Machinena A, Alvaro-Lozano M, Fernandez-Rivas M. Safety of Food Oral Immunotherapy: What We Know, and What We Need to Learn. Immunol Allergy Clin North Am (2020) 40(1):111–33. doi: 10.1016/j.iac.2019.09.013
    PubMed Abstract | CrossRef Full Text | Google Scholar
  21. Burbank AJ, Sood P, Vickery BP, Wood RA. Oral Immunotherapy for Food Allergy. Immunol Allergy Clin North Am (2016) 36(1):55–69. doi: 10.1016/j.iac.2015.08.007
    PubMed Abstract | CrossRef Full Text | Google Scholar
  22. Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the Efficacy of Oral Immunotherapy for the Desensitisation of Peanut Allergy in Children (STOP II): A Phase 2 Randomised Controlled Trial. Lancet (2014) 383(9925):1297–304. doi: 10.1016/S0140-6736(13)62301-6
    PubMed Abstract | CrossRef Full Text | Google Scholar
  23. Virkud YV, Burks AW, Steele PH, Edwards LJ, Berglund JP, Jones SM, et al. Novel Baseline Predictors of Adverse Events During Oral Immunotherapy in Children With Peanut Allergy. J Allergy Clin Immunol (2017) 139(3):882–8 e5. doi: 10.1016/j.jaci.2016.07.030
    PubMed Abstract | CrossRef Full Text | Google Scholar
  24. Vickery BP, Ebisawa M, Shreffler WG, Wood RA. Current and Future Treatment of Peanut Allergy. J Allergy Clin Immunol Pract (2019) 7(2):357–65. doi: 10.1016/j.jaip.2018.11.049
    PubMed Abstract | CrossRef Full Text | Google Scholar
  25. Vazquez-Ortiz M, Alvaro M, Piquer M, Giner MT, Dominguez O, Lozano J, et al. Life-Threatening Anaphylaxis to Egg and Milk Oral Immunotherapy in Asthmatic Teenagers. Ann Allergy Asthma Immunol (2014) 113(4):482–4. doi: 10.1016/j.anai.2014.07.010
    PubMed Abstract | CrossRef Full Text | Google Scholar
  26. Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, et al. Oral Peanut Immunotherapy in Children With Peanut Anaphylaxis. J Allergy Clin Immunol (2010) 126(1):83–91 e1. doi: 10.1016/j.jaci.2010.04.030
    PubMed Abstract | CrossRef Full Text | Google Scholar
  27. Romantsik O, Tosca MA, Zappettini S, Calevo MG. Oral and Sublingual Immunotherapy for Egg Allergy. Cochrane Database Syst Rev (2018) 4:CD010638. doi: 10.1002/14651858.CD010638.pub3
    PubMed Abstract | CrossRef Full Text | Google Scholar
  28. Wasserman RL, Factor JM, Baker JW, Mansfield LE, Katz Y, Hague AR, et al. Oral Immunotherapy for Peanut Allergy: Multipractice Experience With Epinephrine-Treated Reactions. J Allergy Clin Immunol Pract (2014) 2(1):91–6. doi: 10.1016/j.jaip.2013.10.001
    PubMed Abstract | CrossRef Full Text | Google Scholar
  29. Yeung JP, Kloda LA, McDevitt J, Ben-Shoshan M, Alizadehfar R. Oral Immunotherapy for Milk Allergy. Cochrane Database Syst Rev (2012) 11:CD009542. doi: 10.1002/14651858.CD009542.pub2
    PubMed Abstract | CrossRef Full Text | Google Scholar
  30. 63. De Schryver S, Mazer B, Clarke AE, St Pierre Y, Lejtenyi D, Langlois A, et al. Adverse Events in Oral Immunotherapy for the Desensitization of Cow’s Milk Allergy in Children: A Randomized Controlled Trial. J Allergy Clin Immunol Pract (2019) 7(6):1912–9. doi: 10.1016/j.jaip.2019.02.007
    PubMed Abstract | CrossRef Full Text | Google Scholar
  31. Vazquez-Ortiz M, Turner PJ. Improving the Safety of Oral Immunotherapy for Food Allergy. Pediatr Allergy Immunol (2016) 27(2):117–25. doi: 10.1111/pai.12510
  32. PubMed Abstract | CrossRef Full Text | Google Scholar
  33. Itoh-Nagato N, Inoue Y, Nagao M, Fujisawa T, Shimojo N, Iwata T, et al. Desensitization to a Whole Egg by Rush Oral Immunotherapy Improves the Quality of Life of Guardians: A Multicenter, Randomized, Parallel-Group, Delayed-Start Design Study. Allergol Int (2018) 67(2):209–16. doi: 10.1016/j.alit.2017.07.007
  34. PubMed Abstract | CrossRef Full Text | Google Scholar
  35. Vazquez-Ortiz M, Alvaro M, Piquer M, Dominguez O, Giner MT, Lozano J, et al. Impact of Oral Immunotherapy on Quality of Life in Egg-Allergic Children. Pediatr Allergy Immunol (2015) 26(3):291–4. doi: 10.1111/pai.12355
    PubMed Abstract | CrossRef Full Text | Google Scholar
  36. Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of Oral Immunotherapy to Peanut on Food-Specific Quality of Life. Ann Allergy Asthma Immunol (2012) 109(5):348–52 e2. doi: 10.1016/j.anai.2012.08.015
    PubMed Abstract | CrossRef Full Text | Google Scholar
  37. Kukkonen AK, Uotila R, Malmberg LP, Pelkonen AS, Makela MJ. Double-Blind Placebo-Controlled Challenge Showed That Peanut Oral Immunotherapy was Effective for Severe Allergy Without Negative Effects on Airway Inflammation. Acta Paediatr (2017) 106(2):274–81. doi: 10.1111/apa.13668
    PubMed Abstract | CrossRef Full Text | Google Scholar
  38. Reier-Nilsen T, Carlsen KCL, Michelsen MM, Drottning S, Carlsen KH, Zhang C, et al. Parent and Child Perception of Quality of Life in a Randomized Controlled Peanut Oral Immunotherapy Trial. Pediatr Allergy Immunol (2019) 30(6):638–45. doi: 10.1111/pai.13066
    PubMed Abstract | CrossRef Full Text | Google Scholar
  39. Carraro S, Frigo AC, Perin M, Stefani S, Cardarelli C, Bozzetto S, et al. Impact of Oral Immunotherapy on Quality of Life in Children With Cow Milk Allergy: A Pilot Study. Int J Immunopathol Pharmacol (2012) 25(3):793–8. doi: 10.1177/039463201202500329
    PubMed Abstract | CrossRef Full Text | Google Scholar
  40. Otani IM, Begin P, Kearney C, Dominguez TL, Mehrotra A, Bacal LR, et al. Multiple-Allergen Oral Immunotherapy Improves Quality of Life in Caregivers of Food-Allergic Pediatric Subjects. Allergy Asthma Clin Immunol (2014) 10(1):25. doi: 10.1186/1710-1492-10-25
    PubMed Abstract | CrossRef Full Text | Google Scholar
  41. Epstein-Rigbi N, Goldberg MR, Levy MB, Nachshon L, Elizur A. Quality of Life of Food-Allergic Patients Before, During, and After Oral Immunotherapy. J Allergy Clin Immunol Pract (2019) 7(2):429–36 e2. doi: 10.1016/j.jaip.2018.06.016
    PubMed Abstract | CrossRef Full Text | Google Scholar
  42. Rigbi NE, Goldberg MR, Levy MB, Nachshon L, Golobov K, Elizur A. Changes in Patient Quality of Life During Oral Immunotherapy for Food Allergy. Allergy (2017) 72(12):1883–90. doi: 10.1111/all.13211
    PubMed Abstract | CrossRef Full Text | Google Scholar
  43. Epstein Rigbi N, Katz Y, Goldberg MR, Levy MB, Nachshon L, Elizur A. Patient Quality of Life Following Induction of Oral Immunotherapy for Food Allergy. Pediatr Allergy Immunol (2016) 27(3):263–8. doi: 10.1111/pai.12528
    PubMed Abstract | CrossRef Full Text | Google Scholar
  44. Arasi S, Otani IM, Klingbeil E, Begin P, Kearney C, Dominguez TL, et al. Two Year Effects of Food Allergen Immunotherapy on Quality of Life in Caregivers of Children With Food Allergies. Allergy Asthma Clin Immunol (2014) 10(1):57. doi: 10.1186/1710-1492-10-57
    PubMed Abstract | CrossRef Full Text | Google Scholar
  45.  Zhong Y, Chew JL, Tan MM, Soh JY. Efficacy and Safety of Oral Immunotherapy for Peanut Allergy: A Pilot Study in Singaporean Children. Asia Pac Allergy (2019) 9(1):e1. doi: 10.5415/apallergy.2019.9.e1
    PubMed Abstract | CrossRef Full Text | Google Scholar
  46. Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK. Team Ps. The Longitudinal Impact of Probiotic and Peanut Oral Immunotherapy on Health-Related Quality of Life. Allergy (2018) 73(3):560–8. doi: 10.1111/all.13330
    PubMed Abstract | CrossRef Full Text | Google Scholar
  47. Dunn Galvin A, Hourihane JO. Psychosocial Mediators of Change and Patient Selection Factors in Oral Immunotherapy Trials. Clin Rev Allergy Immunol (2018) 55(2):217–36. doi: 10.1007/s12016-018-8700-5
    PubMed Abstract | CrossRef Full Text | Google Scholar
  48. Feuille E, Nowak-Wegrzyn A. Oral Immunotherapy for Food Allergies. Ann Nutr Metab (2016) 68 Suppl 1:19–31. doi: 10.1159/000445391
    PubMed Abstract | CrossRef Full Text | Google Scholar
  49. Saleh-Langenberg J, Goossens NJ, Flokstra-de Blok BM, Kollen BJ, van der Meulen GN, Le TM, et al. Predictors of Health-Related Quality of Life of European Food-Allergic Patients. Allergy (2015) 70(6):616–24. doi: 10.1111/all.12582
    PubMed Abstract | CrossRef Full Text | Google Scholar
  50. Pajno GB, Castagnoli R, Muraro A, Alvaro-Lozano M, Akdis CA, Akdis M, et al. Allergen Immunotherapy for IgE-Mediated Food Allergy: There is a Measure in Everything to a Proper Proportion of Therapy. Pediatr Allergy Immunol (2019) 30(4):415–22. doi: 10.1111/pai.13042
    PubMed Abstract | CrossRef Full Text | Google Scholar
  51. Logan K, Du Toit G, Giovannini M, Turcanu V, Lack G. Pediatric Allergic Diseases, Food Allergy, and Oral Tolerance. Annu Rev Cell Dev Biol (2020) 36:511–28. doi: 10.1146/annurev-cellbio-100818-125346
    PubMed Abstract | CrossRef Full Text | Google Scholar
  52. Sugiura S, Kitamura K, Makino A, Matsui T, Furuta T, Takasato Y, et al. Slow Low-Dose Oral Immunotherapy: Threshold and Immunological Change. Allergol Int (2020) 69(4):601–9. doi: 10.1016/j.alit.2020.03.008
    PubMed Abstract | CrossRef Full Text | Google Scholar
  53. Nowak-Wegrzyn A, Wood RA, Nadeau KC, Pongracic JA, Henning AK, Lindblad RW, et al. Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Vital Wheat Gluten Oral Immunotherapy. J Allergy Clin Immunol (2019) 143(2):651–61 e9. doi: 10.1016/j.jaci.2018.08.041
    PubMed Abstract | CrossRef Full Text | Google Scholar
  54. Kulmala P, Pelkonen AS, Kuitunen M, Paassilta M, Remes S, Schultz R, et al. Wheat Oral Immunotherapy was Moderately Successful But was Associated With Very Frequent Adverse Events in Children Aged 6-18 Years. Acta Paediatr (2018) 107(5):861–70. doi: 10.1111/apa.14226
    PubMed Abstract | CrossRef Full Text | Google Scholar
  55. Elizur A, Appel MY, Nachshon L, Levy MB, Epstein-Rigbi N, Pontoppidan B, et al. Walnut Oral Immunotherapy for Desensitisation of Walnut and Additional Tree Nut Allergies (Nut CRACKER): A Single-Centre, Prospective Cohort Study. Lancet Child Adolesc Health (2019) 3(5):312–21. doi: 10.1016/S2352-4642(19)30029-X
    PubMed Abstract | CrossRef Full Text | Google Scholar
  56. Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, et al. First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy. J Allergy Clin Immunol Pract (2019) 7(8):2759–67 e5. doi: 10.1016/j.jaip.2019.04.010
    PubMed Abstract | CrossRef Full Text | Google Scholar
  57. Bird JA, Spergel JM, Jones SM, Rachid R, Assa’ad AH, Wang J, et al. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. J Allergy Clin Immunol Pract (2018) 6(2):476–85.e3. doi: 10.1016/j.jaip.2017.09.016
    PubMed Abstract | CrossRef Full Text | Google Scholar
  58. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A Randomized Controlled Study of Peanut Oral Immunotherapy: Clinical Desensitization and Modulation of the Allergic Response. J Allergy Clin Immunol (2011) 127(3):654–60. doi: 10.1016/j.jaci.2010.12.1111
    PubMed Abstract | CrossRef Full Text | Google Scholar
  59. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual Versus Oral Immunotherapy for the Treatment of Peanut Allergy. J Allergy Clin Immunol (2015) 135(5):1275–82.e1-6. doi: 10.1016/j.jaci.2014.11.005
    PubMed Abstract | CrossRef Full Text | Google Scholar
  60. Chinthrajah RS, Purington N, Andorf S, Long A, O’Laughlin KL, Lyu SC, et al. Sustained Outcomes in Oral Immunotherapy for Peanut Allergy (POISED Study): A Large, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study. Lancet (2019) 394(10207):1437–49. doi: 10.1016/S0140-6736(19)31793-3
    PubMed Abstract | CrossRef Full Text | Google Scholar
  61. Nagakura KI, Yanagida N, Sato S, Nishino M, Asaumi T, Ogura K, et al. Low-Dose Oral Immunotherapy for Children With Anaphylactic Peanut Allergy in Japan. Pediatr Allergy Immunol (2018) 29(5):512–8. doi: 10.1111/pai.12898
    PubMed Abstract | CrossRef Full Text | Google Scholar
  62. Shaker M, Greenhawt M. Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-Effectiveness Analysis. JAMA Netw Open (2019) 2(5):e193242. doi: 10.1001/jamanetworkopen.2019.3242
    PubMed Abstract | CrossRef Full Text | Google Scholar